Research location
Odense
Region Syddanmark, Denmark
Advertisement
Research activity in Odense
Region Syddanmark, DenmarkCureCurrent currently publishes aggregate city-level research activity for this location: 50 trials and 50 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Odense
50 linked trials · page 1 of 1A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation
RECRUITING
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01 · 1 site observation
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation
RECRUITING
Diagnosing peRipheral Lung Lesions With CRYO BiopsiesNCT06844344 · 2025-03-01 · 1 site observation
RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation
RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation
RECRUITING
Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision AidNCT04880005 · 2021-06-01 · 1 site observation
RECRUITING
Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial HypertensionNCT04032379 · 2018-02-14 · 1 site observation
RECRUITING
Women With Previous GDM and the Effects of HIIT.NCT07566845 · 2026-03-13 · 1 site observation
ENROLLING_BY_INVITATION
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Project Lung Cancer Screening in Southern DenmarkNCT06537804 · 2024-08-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Lymphovenous Anastomosis for Breast Cancer LymphedemaNCT06302361 · 2024-03-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Type 2 Diabetes and Binge Eating Disorder (BED)NCT06325670 · 2024-02-23 · 1 site observation
COMPLETED
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseNCT06107426 · 2024-01-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Generation Healthy Kids: A Cluster-randomized Trial of a Multi-component, Multi-setting InterventionNCT05940675 · 2023-08-14 · 1 site observation
COMPLETED
Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe PatientsNCT05575336 · 2023-02-01 · 1 site observation
COMPLETED
Lymphaticovenous Anastomosis as Treatment for LymphedemaNCT05441943 · 2022-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection FractionNCT04996550 · 2022-01-03 · 1 site observation
NOT_YET_RECRUITING
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT04819100 · 2021-12-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation
TERMINATED
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).NCT04895722 · 2021-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisNCT04842981 · 2021-05-25 · 1 site observation
TERMINATED
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)NCT04725188 · 2021-04-20 · 1 site observation
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)NCT04776148 · 2021-03-29 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · 2021-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Navigation Endobronchial UltrasoundNCT04553809 · 2020-10-12 · 1 site observation
COMPLETED
Metformin's Effect on Drug Metabolism in Patients With Type 2 DiabetesNCT04504045 · 2020-09-01 · 1 site observation
TERMINATED
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.NCT05266300 · 2020-09-01 · 1 site observation
COMPLETED
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's DiseaseNCT04379050 · 2020-06-08 · 1 site observation
COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177 · 2020-05-22 · 1 site observation
TERMINATED
COVID-19 Pandemic Impact on Patients With Cancer - a Danish SurveyNCT04389996 · 2020-05-14 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)NCT04210115 · 2020-02-28 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation
TERMINATED
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)NCT03924856 · 2019-06-13 · 1 site observation
COMPLETED
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation
COMPLETED
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)NCT03675737 · 2018-11-08 · 1 site observation
COMPLETED
Weight Loss and Reversing T2D Through eHealth CoachingNCT03788915 · 2018-04-16 · 1 site observation
UNKNOWN
REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)NCT05029167 · 2017-09-11 · 1 site observation
UNKNOWN
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Breathing Exercises in Asthma Targeting Dysfunctional BreathingNCT03127059 · 2017-04-27 · 1 site observation
COMPLETED
Pulsed Electro Magnetic Fields (PEMF) in DepressionNCT03556735 · 2016-09-01 · 1 site observation
COMPLETED
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCNCT02409368 · 2015-04-29 · 1 site observation
COMPLETED
Effect of Physical Therapy on Breast Cancer Related LymphedemaNCT02015897 · 2014-01-01 · 1 site observation
COMPLETED
AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in ChildrenNCT02068573 · 2012-08-01 · 1 site observation
COMPLETED
Ulcer Monitoring in Diabetes MellitusNCT01608425 · 2011-04-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.